Price Target https://www.benzinga.com/views/taxonomy/term/72 en Uber, GrubHub Analysts Dish Opinions On Reported M&A Talks: 'Not Surprising' https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16014046/uber-grubhub-analysts-dish-opinions-on-reported-m-a-talks-not-surprising <p>If <a href="https://www.benzinga.com/m-a/20/05/16012531/uber-looking-to-eat-up-grubhub-reports">media reports</a> are accurate that <strong>Uber Technologies Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) is in talks to acquire rival food delivery platform <strong>GrubHub Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grub#NYSE">GRUB</a>), it would be both an offensive and defensive move, according to Wedbusgh.</p> <h3>The Uber Analysts</h3> <p>Wedbush analyst <a href="https://www.tipranks.com/analysts/ygal-arounian">Ygal Arounian</a> maintains an Outperform rating on Uber&nbsp;with an unchanged $38 price target.</p> <p>Needham analyst <a href="https://www.tipranks.com/analysts/brad-erickson">Brad Erickson</a> maintains a Buy rating on Uber&#39;s stock with a $42 price target and a Hold rating on GrubHub&#39;s stock.</p> <p>D.A. Davidson analyst <a href="https://www.tipranks.com/analysts/tom-forte">Tom Forte</a> maintains an Underperform rating on GrubHub&nbsp;stock with an unchanged $31 price target.</p> <p>KeyBanc Capital Markets analyst Edward Yruma upgraded GrubHub from Underweight to Sector Weight.</p> <h3>The Wedbush Thesis</h3> <p>Uber&#39;s potentially &quot;aggressive move&quot; to acquire a rival comes at a time when the COVID-19 pandemic forces consumers to place more restaurant orders compared to ride-sharing requests, Arounian said&nbsp;in a note.</p> <p>Despite a large increase in food order&nbsp;requests, profit for the group as a whole remains a &quot;meaningful headwind,&quot; the analyst said.&nbsp;</p> <p>If an acquisition is confirmed, Uber would control 55% of the entire market in third-party food delivery, which would give it a &quot;clear leader&quot; status, he said.</p> <p>This would mark the first time since the end of 2017 that one entity controlled more than half of ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16014046/uber-grubhub-analysts-dish-opinions-on-reported-m-a-talks-not-surprising alt=Uber, GrubHub Analysts Dish Opinions On Reported M&amp;A Talks: &#039;Not Surprising&#039;>Full story available on Benzinga.com</a></p> Analyst Color Brad Erickson DA Davidson food Food Delivery GRUB M&A Needham Restaurant Delivery Tom Forte UBER Wedbush Ygal Arounian Upgrades Price Target Reiteration Restaurants Analyst Ratings General GRUB UBER M&A Analyst Color Upgrades Price Target Reiteration Restaurants Analyst Ratings General Benzinga Tue, 12 May 2020 20:34:57 +0000 Jayson Derrick 16014046 at https://www.benzinga.com Analyst: Black & Decker's Defensive Margin Strategy May Stunt Competitiveness https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16010576/analyst-black-deckers-defensive-margin-strategy-may-stunt-competitiveness <p><strong>Stanley Black &amp; Decker, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/swk#NYSE">SWK</a>) has recovered some of its March coronavirus losses, but it still trades down 16% year over year and 33% year to date. One analyst team sees limits to the company&rsquo;s recovery.</p> <h3><strong>The Black &amp; Decker Rating</strong></h3> <p>Bank of America analysts <a href="https://www.tipranks.com/analysts/ross-gilardi">Ross Gilardi</a> and Michael Feniger downgraded <a href="https://www.benzinga.com/stock/swk">Stanley Black &amp; Decker</a> to Neutral and cut their price target from $121 to $120.</p> <h3><strong>The Black &amp; Decker Thesis</strong></h3> <p>In the last few years, Stanley has taken great pains to protect its margins from trade wars, and in the last few months, it&rsquo;s determined to cut another $1 billion in costs to mitigate ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16010576/analyst-black-deckers-defensive-margin-strategy-may-stunt-competitiveness alt=Analyst: Black &amp; Decker&#039;s Defensive Margin Strategy May Stunt Competitiveness>Full story available on Benzinga.com</a></p> Analyst Color Bank of America Michael Feniger Ross Gilardi SWK Downgrades Price Target Analyst Ratings SWK US8545021011 Analyst Color Downgrades Price Target Analyst Ratings Benzinga Tue, 12 May 2020 20:22:31 +0000 Elizabeth Balboa 16010576 at https://www.benzinga.com Wedbush Upgrades CarMax On Potential For Strong Post-Coronavirus Recovery https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16011199/wedbush-upgrades-carmax-on-potential-for-strong-post-coronavirus-recovery <p><strong>CarMax, Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmx#NYSE">KMX</a>) seems well-positioned to bounce back and capture market share as the economy emerges from the coronavirus pandemic, according to Wedbush.</p> <h3>The CarMax Analyst</h3> <p><a href="https://www.tipranks.com/analysts/seth-basham">Seth Basham</a> upgraded&nbsp;CarMax from Neutral to Outperform and raised&nbsp;the price target from $70 to $90.</p> <h3>The CarMax Thesis</h3> <p>Wedbush&rsquo;s proprietary sales tracker suggests an improvement in CarMax&rsquo;s used unit comps through April to a run rate of negative 38%, Basham said in the Tuesday upgrade note. (See his track record <a href="http://www.tipranks.com/analysts/seth-basham">here</a>.)</p> <p>This run rate could improve further to negative 30% as states ease stay-at-home restrictions and more of the company&rsquo;s stores become fully operational, the analyst ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16011199/wedbush-upgrades-carmax-on-potential-for-strong-post-coronavirus-recovery alt=Wedbush Upgrades CarMax On Potential For Strong Post-Coronavirus Recovery>Full story available on Benzinga.com</a></p> Analyst Color KMX Seth Basham Wedbush Upgrades Price Target Analyst Ratings KMX US1431301027 Analyst Color Upgrades Price Target Analyst Ratings Benzinga Tue, 12 May 2020 19:37:28 +0000 Priya Nigam 16011199 at https://www.benzinga.com Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16012507/inovio-analysts-tackle-coronavirus-vaccine-timeline-funding-pipeline-after-q1-repor <p>Despite <strong>Inovio Pharmaceuticals Inc&#39;s </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>)&nbsp;<a href="https://www.benzinga.com/general/biotech/20/05/16005335/inovio-q1-results-miss-estimates-coronavirus-vaccine-program-on-track">first-quarter miss Monday</a>, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate.&nbsp;</p> <h3>The Inovio Analysts</h3> <p>Stifel analyst <a href="http://https://www.tipranks.com/analysts/stephen-willey">Stephen Wiley</a> maintained a Buy rating and $19 price target for Inovio shares.</p> <p>H.C. Wainwright analyst <a href="http://https://www.tipranks.com/analysts/ram-selvaraju">Raghuram Selvaraju</a> reiterated a Buy rating and $17 price target.&nbsp;</p> <h3>Stifel Sees Viable Pathway For External Funding</h3> <p>The ongoing Phase 1 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15875749/a-deep-dive-on-coronavirus-vaccine-plays-moderna-inovio"> INO-4800 development program </a> for the new coronavirus is likely to remain a source of continued volatility in the light of the emerging competitive landscape, Stifel analyst Wiley said in a Monday note.</p> <p>Inovio stated that all healthy volunteers will receive the second dose of INO-4800 by the end of May and preliminary safety and&nbsp;immunogenicity data will be available in late June, the analyst said.</p> <p>The company expects the vaccine to be available under emergency use authorization ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16012507/inovio-analysts-tackle-coronavirus-vaccine-timeline-funding-pipeline-after-q1-repor alt=Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report>Full story available on Benzinga.com</a></p> Analyst Color Biotech Coronavirus Covid-19 Earnings H.C. Wainwright INO INO-4800 News Raghuram Selvaraju Stephen Wiley Stifel Health Care Price Target Reiteration Analyst Ratings Movers Trading Ideas General INO US45773H1023 News Analyst Color Earnings Biotech Health Care Price Target Reiteration Analyst Ratings Movers Trading Ideas General Benzinga Tue, 12 May 2020 18:49:28 +0000 Shanthi Rexaline 16012507 at https://www.benzinga.com Why Grocery Outlet's Stock Is Trading Higher Today https://www.benzinga.com/news/earnings/20/05/16014137/why-grocery-outlets-stock-is-trading-higher-today <p><strong>Grocery Outlet </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/go#NASDAQ">GO</a>) shares are trading higher on Tuesday&nbsp;after reporting first-quarter earnings.</p> <p>Grocery Outlet reported quarterly earnings of 36c cents per share, which beat the analyst consensus estimate of 25 cents. The company reported quarterly sales of $760.3 million, which beat the analyst consensus estimate of $755.59 million.</p> <p>Deutsche Bank maintained a Buy rating and raised its price target from $42 to $43. Morgan Stanley ...</p><p><a href=https://www.benzinga.com/news/earnings/20/05/16014137/why-grocery-outlets-stock-is-trading-higher-today alt=Why Grocery Outlet&#039;s Stock Is Trading Higher Today>Full story available on Benzinga.com</a></p> Earnings GO News why it's moving Price Target Analyst Ratings GO News Earnings Price Target Analyst Ratings Benzinga Tue, 12 May 2020 18:45:53 +0000 Tanzeel Akhtar 16014137 at https://www.benzinga.com Why Athene's Stock Is Trading Lower Today https://www.benzinga.com/news/20/05/16014087/why-athenes-stock-is-trading-lower-today <p><strong>Athene Holding Ltd</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ath#NYSE">ATH</a>) shares are trading lower on Tuesday, after SunTrust Robinson Humphrey lowered its price target on the stock from $61 to $45.</p> <p>Athene Holding is a retirement services company. It issues, reinsures and acquires retirement savings products designed for the increasing number of individuals and institutions seeking ...</p><p><a href=https://www.benzinga.com/news/20/05/16014087/why-athenes-stock-is-trading-lower-today alt=Why Athene&#039;s Stock Is Trading Lower Today>Full story available on Benzinga.com</a></p> ATH News why it's moving Price Target Analyst Ratings ATH News Price Target Analyst Ratings Benzinga Tue, 12 May 2020 18:43:16 +0000 Tanzeel Akhtar 16014087 at https://www.benzinga.com Why MyoKardia's Stock Is Trading Higher Today https://www.benzinga.com/news/20/05/16014000/why-myokardias-stock-is-trading-higher-today <p><strong>MyoKardia </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myok#NASDAQ">MYOK</a>) shares are trading higher on Tuesday.</p> <p>On Monday, the company announced the primary and secondary endpoints for its Phase 3 EXPLORER clinical trials of Mavacamten were met. Also, Citi and Morgan Stanley analysts raised their price targets on Tuesday.</p> <p>MyoKardia is a U.S.-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing ...</p><p><a href=https://www.benzinga.com/news/20/05/16014000/why-myokardias-stock-is-trading-higher-today alt=Why MyoKardia&#039;s Stock Is Trading Higher Today>Full story available on Benzinga.com</a></p> MYOK News why it's moving Health Care Price Target Analyst Ratings General MYOK News Health Care Price Target Analyst Ratings General Benzinga Tue, 12 May 2020 18:42:08 +0000 Tanzeel Akhtar 16014000 at https://www.benzinga.com Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16013328/novavax-analysts-say-cepi-funding-speaks-volumes-about-coronavirus-vaccine-developm <p><strong>Novavax, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results.</p> <h3>The Novavax Analysts</h3> <p>H.C. Wainwright analyst <a href="http://https://www.tipranks.com/analysts/vernon-bernardino">Vernon Bernardino</a> reiterated a Buy rating on <a href="https://www.benzinga.com/short-sellers/20/04/15842144/novavax-continues-huge-run-short-seller-sees-stock-falling-back-to-15"> Novavax shares </a> and increased the price target from $33 to $50.&nbsp;&nbsp;</p> <p>B Riley FBR analyst <a href="http://https://www.tipranks.com/analysts/mayank-mamtani">Mayank Mamtani</a> maintained a Buy rating and hiked the price target from $29 to $43.&nbsp;&nbsp;</p> <p>Oppenheimer analyst <a href="http://www.tipranks.com/analysts/kevin-degeeter">Kevin DeGeeter</a> maintained an Outperform rating and lifted the price target from $19 to $38.50.&nbsp;</p> <h3>Novavax&#39;s Prior Vaccine Experience&nbsp;Is Underappreciated, H.C. Wainwright Says</h3> <p>H.C. Wainwright is focused on <a href="https://www.benzinga.com/general/biotech/20/03/15650188/novavax-shares-rally-on-flu-vaccine-study-results-what-you-need-to-know"> positive top-line results </a> for Novavax&#39;s pivotal Phase 3 clinical trial for&nbsp;NanoFlu, its Matrix-M adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for adults 65 and older, Bernardino said in a Tuesday note.</p> <p>The analyst is of the view that NanoFlu has a clear path to licensure.</p> <p>A BLA filing for NanoFlu could occur later this year, opening up the possibility of potential commercialization in time for the start of the 2020-2021 flu season, he said.&nbsp;</p> <p>With the CEPI funding for Novavax&#39;s SARS-CoV-2 vaccine candidate NVX-CoV2373, ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16013328/novavax-analysts-say-cepi-funding-speaks-volumes-about-coronavirus-vaccine-developm alt=Novavax Analysts Say CEPI Funding &#039;Speaks Volumes&#039; About Coronavirus Vaccine Development>Full story available on Benzinga.com</a></p> Analyst Color B Riley FBR Biotech CEPI Coronavirus Covid-19 Earnings H.C. Wainwright JNJ Kevin DeGeeter Mayank Mamtani MRNA News NVAX Oppenheimer SNY Vernon Bernardino Health Care Price Target Reiteration Top Stories Analyst Ratings Trading Ideas General NVAX US6700021040 JNJ US4781601046 SNY US80105N1054 MRNA US56804Q1022 News Analyst Color Earnings Biotech Health Care Price Target Reiteration Top Stories Analyst Ratings Trading Ideas General Benzinga Tue, 12 May 2020 18:08:54 +0000 Shanthi Rexaline 16013328 at https://www.benzinga.com Tilray Investors Overreacted To A Good Q1 Print, Says Cantor Fitzgerald https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16010847/tilray-investors-overreacted-to-a-good-q1-print-says-cantor-fitzgerald <p><strong>Tilray Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) reported stable first-quarter results Monday, beating expectations across key metrics.</p> <p>Given this performance and upbeat management commentary around the COVID-19 impact on sales in the Canadian cannabis industry, the pressure on the company&rsquo;s stock is surprising, according to Cantor Fitzgerald.</p> <h3>The Tilray Analyst</h3> <p><a href="https://www.tipranks.com/analysts/pablo-zuanic">Pablo Zuanic</a> maintained a Neutral rating for Tilray and raised the price target from $7 to $8.</p> <h3>The Tilray Thesis</h3> <p>Tilray reported first-quarter sales of $52.1 million, ahead of the consensus estimate of $49.3 million and&nbsp;driven largely by its hemp foods business, Zuanic said in a Monday note. (See his track ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16010847/tilray-investors-overreacted-to-a-good-q1-print-says-cantor-fitzgerald alt=Tilray Investors Overreacted To A Good Q1 Print, Says Cantor Fitzgerald>Full story available on Benzinga.com</a></p> Analyst Color Cannabis Cantor Fitzgerald COST Earnings News Pablo Zuanic TLRY Guidance Price Target Reiteration Markets Analyst Ratings COST US22160K1051 TLRY US88688T1007 News Analyst Color Earnings Cannabis Guidance Price Target Reiteration Markets Analyst Ratings Benzinga Tue, 12 May 2020 16:17:31 +0000 Priya Nigam 16010847 at https://www.benzinga.com Analyst Polishes Apple Price Target On 'Teflon-Like' Services, iPhone 12 Outlook https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16010047/analyst-polishes-apple-price-target-on-teflon-like-services-iphone-12-outlook <p>As one of the first U.S. businesses disrupted by the coronavirus, <strong>Apple Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) seemed to be a model of superior <a href="https://www.benzinga.com/news/20/05/15951774/apple-capitalizes-on-plunge-in-yields-issues-cheapest-bonds-in-years">survival</a> techniques. Now, Apple is approaching future catalysts from a position of strength,&nbsp;according to Wedbush.</p> <h3>The Apple Analyst</h3> <p><a href="https://www.tipranks.com/analysts/daniel-ives">Daniel Ives</a>&nbsp;maintained an Outperform rating on Apple and&nbsp;raised the&nbsp;price target from $335 to $350.</p> <h3>The Apple Thesis</h3> <p>For the most part, Apple has remained unshaken by COVID-19, according to Wedbush.</p> <p>Its global demand and supply chain have weathered the storm. Yet the lengthening of global lockdowns and the impending economic fallout are expected to delay the company&rsquo;s recovery, in the research firm&#39;s view.&nbsp;</p> <p>&ldquo;To this point, we have continued to encourage investors to use this near-term uncertainty ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16010047/analyst-polishes-apple-price-target-on-teflon-like-services-iphone-12-outlook alt=Analyst Polishes Apple Price Target On &#039;Teflon-Like&#039; Services, iPhone 12 Outlook>Full story available on Benzinga.com</a></p> AAPL Analyst Color Daniel Ives iPhone Wedbush Price Target Reiteration Top Stories Analyst Ratings Tech AAPL US0378331005 Analyst Color Price Target Reiteration Top Stories Analyst Ratings Tech Benzinga Tue, 12 May 2020 14:58:17 +0000 Elizabeth Balboa 16010047 at https://www.benzinga.com 10 Biggest Price Target Changes For Tuesday https://www.benzinga.com/markets/penny-stocks/20/05/16009423/10-biggest-price-target-changes-for-tuesday <ul> <li>H.C. Wainwright boosted the price target for <strong> Pulse Biosciences Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plse#NASDAQ">PLSE</a>) from $6 to $16. Pulse Biosciences closed at $11.74 on Monday.</li> <li>Rosenblatt lifted <strong> Datadog Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>) price target from $61 to $75. Datadog closed at $55.69 on Monday.</li> <li>Needham raised the price target on <strong> II-VI, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iivi#NASDAQ">IIVI</a>) from $40 to $52. II-VI shares closed at $36.24 on Monday.</li> <li>Goldman Sachs cut the price ...</li></ul><p><a href=https://www.benzinga.com/markets/penny-stocks/20/05/16009423/10-biggest-price-target-changes-for-tuesday alt=10 Biggest Price Target Changes For Tuesday>Full story available on Benzinga.com</a></p> ALB CBAY CCXI CMI DDOG EVLO IIVI PCAR Penny Stocks PLSE Price Target Changes UAA Price Target Pre-Market Outlook Analyst Ratings IIVI US9021041085 PCAR US6937181088 ALB US0126531013 CMI US2310211063 CCXI CBAY EVLO PLSE UAA DDOG Penny Stocks Price Target Pre-Market Outlook Analyst Ratings Benzinga Tue, 12 May 2020 12:03:41 +0000 Lisa Levin 16009423 at https://www.benzinga.com Boyd Gaming Vs. Penn National: Which Stock Is The Better Casino Rebound Trade? https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16003236/boyd-gaming-vs-penn-national-which-stock-is-the-better-casino-rebound-trade <p>Casino stocks have had a rough year in 2020 due to coronavirus (COVID-19) shutdowns. However, some long-term gambling bulls believe business will get back to normal for gamblers as soon as casinos reopen.</p> <p>Two of the most popular regional U.S. casino operators are <strong>Boyd Gaming Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/byd#NYSE">BYD</a>) and <strong>Penn National Gaming, Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/penn#NASDAQ">PENN</a>), and both stocks have taken a beating this year. Boyd shares are down 39.6% year to date, while Penn shares are down 26.5%.</p> <p>There is a bull case to be made for both stocks at this point. Here&rsquo;s how they stack up against one another.</p> <p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/05/15933525/the-road-to-recovery-for-las-vegas-casino-stocks">The Road To Recovery For Las Vegas Casino Stocks </a></em></p> <h3><strong>The Boyd Bull Case</strong></h3> <p>Boyd operates about 30 gaming facilities in 10 different U.S. states, including 12 properties in and around the Las Vegas area. Las Vegas casinos remain closed at this point, but Bank of America analyst <a href="https://www.tipranks.com/analysts/shaun-kelley">Shaun Kelley </a>recently said some properties could start opening back up in late May, while others could reopen in early June.</p> <p>In the meantime, Kelley said Boyd&rsquo;s stellar balance sheet will help it get through the shutdown. As of March 31, Boyd had $4.44 billion in total debt and $831.2 million in cash on hand.</p> <p>&ldquo;BYD&rsquo;s strong balance sheet should see it through and it has ample flexibility/levers ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16003236/boyd-gaming-vs-penn-national-which-stock-is-the-better-casino-rebound-trade alt=Boyd Gaming Vs. Penn National: Which Stock Is The Better Casino Rebound Trade?>Full story available on Benzinga.com</a></p> Analyst Color Bank of America Barstool Sports BYD casinos gambling Long Ideas online gambling PENN Shaun Kelley Steven Wieczynski Stifel Price Target Top Stories Analyst Ratings Trading Ideas PENN US7075691094 BYD US1033041013 Long Ideas Analyst Color Price Target Top Stories Analyst Ratings Trading Ideas Benzinga Mon, 11 May 2020 19:16:43 +0000 Wayne Duggan 16003236 at https://www.benzinga.com Why Nvidia Has A New Street-High Price Target https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16002288/why-nvidia-has-a-new-street-high-price-target <p><strong>NVIDIA Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) is scheduled to report its fiscal year 2021&nbsp;first-quarter results May 21&nbsp;after the close. Ahead of the results, and following the recent strong run&nbsp;in the&nbsp;shares, an analyst at Needham hiked their Nvidia price target to a Street-high number.</p> <h3>The Nvidia Analyst</h3> <p>Analyst <a href="https://www.tipranks.com/analysts/rajvindra-gill">Rajvindra Gill</a> maintained a Buy rating and increased the price target from $270 to $360. (See his track record <a href=" https://www.tipranks.com/analysts/rajvindra-gill"> here</a> )</p> <h3>The Nvidia Thesis</h3> <p>The positive Nvidia story hinges on three pillars, Gill said in a Monday note: the chipmaker&#39;s&nbsp;recently completed <a href="https://www.benzinga.com/m-a/20/04/15891888/ive-been-dreaming-about-this-nvidia-ceo-says-after-7b-mellanox-acquisition-deal-finally-closed"> Mellanox acquisition, </a> strong gaming sales and solid data center performance. (See his&nbsp;track record <a href="https://www.tipranks.com/analysts/rajvindra-gill">here</a>.)</p> <p>The analyst said Mellanox results have improved meaningfully since ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16002288/why-nvidia-has-a-new-street-high-price-target alt=Why Nvidia Has A New Street-High Price Target>Full story available on Benzinga.com</a></p> Analyst Color gaming Needham NTDOY NVDA Rajvindra Gill video games Price Target Reiteration Top Stories Analyst Ratings Tech NVDA US67066G1040 NTDOY US6544453037 Analyst Color Price Target Reiteration Top Stories Analyst Ratings Tech Benzinga Mon, 11 May 2020 19:06:30 +0000 Shanthi Rexaline 16002288 at https://www.benzinga.com ViacomCBS Subscription Numbers Make Barrington Bullish https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16001158/viacomcbs-subscription-numbers-make-barrington-bullish <p><strong>ViacomCBS Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viac#NASDAQ">VIAC</a>) has made better-than-expected progress in direct-to-consumer subscriber growth and there are early signs of success of its integration efforts, according to Barrington Research.</p> <h3>The ViacomCBS Analyst</h3> <p>Barrington&rsquo;s <a href="https://www.tipranks.com/analysts/james-goss">James Goss</a> reinstated coverage of ViacomCBS with an Outperform rating and $30&nbsp;price target.&nbsp;</p> <h3>The ViacomCBS Thesis</h3> <p>It was in question&nbsp;whether the newly combined ViacomCBS entity would be able to smoothly integrate assets amid the COVID-19 pandemic, Goss said in a Monday note. (See his track record <a href="http://www.tipranks.com/analysts/james-goss">here</a>.)</p> <p>Although key revenue and profitability metrics declined in the quarter, both reported and prospective subscriber ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16001158/viacomcbs-subscription-numbers-make-barrington-bullish alt=ViacomCBS Subscription Numbers Make Barrington Bullish>Full story available on Benzinga.com</a></p> Analyst Color Barrington Research James Goss VIAC Price Target Analyst Ratings VIAC Analyst Color Price Target Analyst Ratings Benzinga Mon, 11 May 2020 18:43:06 +0000 Priya Nigam 16001158 at https://www.benzinga.com Why AbbVie's Stock Is Trading Higher Today https://www.benzinga.com/news/20/05/16003203/why-abbvies-stock-is-trading-higher-today <p><strong>AbbVie</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) shares are trading higher on Monday.</p> <p>Morgan Stanley analysts reinstated coverage on AbbVie with an Overweight rating and $95 price target, saying they view Humira erosion fears as &quot;overly discounted&quot; and that they see a &quot;positive risk-reward skew&quot; given the company&#39;s dividend yield.</p> <p>AbbVie is a drug company with a strong exposure to immunology and oncology. The company&#39;s top ...</p><p><a href=https://www.benzinga.com/news/20/05/16003203/why-abbvies-stock-is-trading-higher-today alt=Why AbbVie&#039;s Stock Is Trading Higher Today>Full story available on Benzinga.com</a></p> ABBV why it's moving Price Target Initiation Analyst Ratings Movers Trading Ideas ABBV Price Target Initiation Analyst Ratings Movers Trading Ideas Benzinga Mon, 11 May 2020 18:30:48 +0000 Tanzeel Akhtar 16003203 at https://www.benzinga.com